Gilead Sciences Inc. (GILD)
Analysis of Revenues
Accounting Policy on Revenue Recognition
On January 1, 2018, Gilead adopted Accounting Standards Update No. 2014-09 “Revenue from Contracts with Customers” (Topic 606) using the modified retrospective method. Topic 606 supersedes the revenue recognition requirements in Topic 605 “Revenue Recognition” (Topic 605). As a result, Gilead has changed the accounting policies for revenue recognition as detailed below.
Gilead recognizes revenue from product sales when control of the product transfers, generally upon shipment or delivery, to the customer, or in certain cases, upon the corresponding sales by the customer to a third party. Upon recognition of revenue from product sales, provisions are made for various forms of variable consideration, which include government and other rebates such as Medicaid reimbursements, customer incentives such as cash discounts for prompt payment, distributor fees and expected returns of expired products, as appropriate. Gilead’s payment terms to customers generally range from 30 to 90 days.
Royalty, Contract and Other Revenues
Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by Gilead’s corporate partners occur.
Source: 10-K (filing date: 2019-02-26).
Revenues as Reported
Gilead Sciences Inc., Income Statement, Revenues
US$ in millions
|Product sales||Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).||Gilead Sciences Inc.’s product sales decreased from 2016 to 2017 and from 2017 to 2018.|